Your browser is no longer supported. Please, upgrade your browser.
Settings
ZGNX Zogenix, Inc. daily Stock Chart
ZGNX [NASD]
Zogenix, Inc.
Index- P/E- EPS (ttm)-3.21 Insider Own35.10% Shs Outstand25.30M Perf Week-5.24%
Market Cap320.04M Forward P/E- EPS next Y-3.14 Insider Trans0.06% Shs Float22.51M Perf Month15.00%
Income-79.60M PEG- EPS next Q-0.89 Inst Own89.70% Short Float20.17% Perf Quarter19.34%
Sales22.30M P/S14.35 EPS this Y-42.50% Inst Trans0.55% Short Ratio22.38 Perf Half Y-6.30%
Book/sh4.08 P/B3.10 EPS next Y13.50% ROA- Target Price21.75 Perf Year26.50%
Cash/sh- P/C- EPS next 5Y25.00% ROE- 52W Range7.33 - 13.82 Perf YTD4.12%
Dividend- P/FCF- EPS past 5Y29.30% ROI-50.20% 52W High-8.50% Beta1.91
Dividend %- Quick Ratio4.90 Sales past 5Y-5.10% Gross Margin24.50% 52W Low72.58% ATR0.52
Employees67 Current Ratio5.40 Sales Q/Q-70.70% Oper. Margin- RSI (14)56.35 Volatility3.52% 4.84%
OptionableYes Debt/Eq0.22 EPS Q/Q-106.40% Profit Margin- Rel Volume0.61 Prev Close12.90
ShortableYes LT Debt/Eq0.17 EarningsMay 04 AMC Payout- Avg Volume202.96K Price12.65
Recom1.60 SMA202.89% SMA5012.03% SMA20020.01% Volume124,532 Change-1.94%
Oct-04-16Resumed Leerink Partners Outperform $17
Aug-11-15Reiterated Oppenheimer Outperform $20 → $23
Jul-15-15Reiterated Brean Capital Buy $20 → $28
Apr-22-15Initiated Piper Jaffray Overweight $2.50
Dec-29-14Initiated Brean Capital Buy $2.50
Jun-06-14Initiated R. F. Lafferty Buy $3.50
Oct-29-13Upgrade Stifel Hold → Buy $5
Jun-21-13Resumed Oppenheimer Perform
Mar-05-13Initiated Brinson Patrick Market Outperform
Dec-10-12Downgrade Stifel Nicolaus Buy → Hold
Dec-10-12Downgrade Oppenheimer Outperform → Perform $3
Jan-06-12Initiated William Blair Outperform
Sep-26-11Reiterated Oppenheimer Outperform $9 → $5
Jan-06-11Initiated Oppenheimer Outperform $9
Jan-03-11Initiated Stifel Nicolaus Buy $10
May-22-17 08:00AM  Zogenix Announces Presentation of ZX008 Mechanism of Action Data at Annual Meeting of Society of Biological Psychiatry GlobeNewswire
May-11-17 05:50PM  ETFs with exposure to Zogenix, Inc. : May 11, 2017 Capital Cube
08:21AM  Edited Transcript of ZGNX earnings conference call or presentation 4-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-09-17 11:00AM  Zogenix, Inc. :ZGNX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017 Capital Cube
May-04-17 06:25PM  Zogenix reports 1Q loss Associated Press
04:01PM  Zogenix Provides Corporate Update and Reports First Quarter 2017 Financial Results GlobeNewswire
09:35AM  Investor Network: Zogenix, Inc. to Host Earnings Call Accesswire
May-01-17 08:15AM  Blog Coverage Zogenix Announces Completion of Enrollment for the Phase III Trial in Dravet Syndrome Accesswire
Apr-27-17 08:01AM  Zogenix Completes Enrollment in First ZX008 Phase 3 Clinical Trial in Dravet Syndrome GlobeNewswire
08:00AM  Zogenix to Release First Quarter 2017 Financial Results and Host Conference Call and Webcast on May 4 GlobeNewswire
Apr-17-17 01:13PM  ETFs with exposure to Zogenix, Inc. : April 17, 2017 Capital Cube
Apr-05-17 05:48PM  ETFs with exposure to Zogenix, Inc. : April 5, 2017 Capital Cube
Mar-20-17 12:10PM  Zogenix, Inc. :ZGNX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Capital Cube
Mar-15-17 01:15PM  Zogenix, Inc. :ZGNX-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017 Capital Cube
01:04PM  ZOGENIX, INC. Financials
08:00AM  Zogenix to Participate in the Oppenheimer 27th Annual Healthcare Conference GlobeNewswire
Mar-10-17 07:15AM  ZOGENIX, INC. Files SEC form 10-K, Annual Report +13.09%
Mar-09-17 05:26PM  Zogenix reports 4Q loss Associated Press
04:05PM  ZOGENIX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:01PM  Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results GlobeNewswire
07:07AM  Q4 2016 Zogenix Inc Earnings Release - After Market Close
Mar-02-17 08:00AM  Zogenix to Release Fourth Quarter and Full-Year 2016 Financial Results and Host Conference Call and Webcast on March 9 GlobeNewswire
Mar-01-17 08:00AM  Zogenix Receives Orphan Drug Designation in the European Union for ZX008 in Lennox Gastaut Syndrome GlobeNewswire
06:17AM  ZOGENIX, INC. Files SEC form 8-K, Other Events
Feb-15-17 08:00AM  Zogenix to Participate in the 2017 RBC Capital Markets Healthcare Conference GlobeNewswire +11.92%
Feb-13-17 08:00AM  Zogenix Announces Initiation of Clinical Efficacy Portion of Study 1504 for ZX008 in Dravet Syndrome GlobeNewswire
Feb-08-17 08:00AM  Zogenix to Participate in the Leerink Partners 6th Annual Global Healthcare Conference GlobeNewswire +8.24%
Jan-30-17 08:01AM  ZOGENIX, INC. Files SEC form 8-K, Other Events
08:00AM  Zogenix Announces Issuance of U.S. Patent for ZX008 in Dravet Syndrome GlobeNewswire
Jan-26-17 08:15AM  Blog Coverage Novartis Announced Buyback of Shares Worth $5 Billion; Considers Strategic Options for Alcon Division Accesswire
Jan-09-17 08:32AM  ZOGENIX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial
Jan-05-17 04:03PM  ZOGENIX, INC. Files SEC form 8-K, Change in Directors or Principal Officers
04:01PM  Zogenix Announces CFO Transition GlobeNewswire
Dec-21-16 01:06PM  ETFs with exposure to Zogenix, Inc. : December 21, 2016
Dec-09-16 08:48AM  Is Foamix Pharmaceuticals Ltd (FOMX) Going to Burn These Hedge Funds? at Insider Monkey
Dec-08-16 10:19AM  Is Zogenix Stock Still a Buy After Soaring in November? at Motley Fool
Dec-05-16 08:31AM  ZOGENIX, INC. Files SEC form 8-K, Other Events
08:00AM  Zogenix Announces New Efficacy and Safety Data for ZX008 in Treatment of Seizures in Lennox Gastaut Syndrome & Dravet Syndrome GlobeNewswire
Dec-02-16 11:49AM  Hedge Funds Are Piling Back Into Zogenix, Inc. (ZGNX): Should You Follow? at Insider Monkey
Nov-30-16 08:53AM  Earnings Estimates Moving Higher for Zogenix (ZGNX): Time to Buy?
Nov-23-16 10:45AM  Moving Average Crossover Alert: Zogenix (ZGNX)
Nov-22-16 04:05PM  New Data on Zogenixs ZX008 for Lennox Gastaut Syndrome & Dravet Syndrome to be Presented at 70th Annual American Epilepsy Society Meeting GlobeNewswire
08:00AM  Zogenix to Participate in Oppenheimer Life Sciences Summit 2016 GlobeNewswire
Nov-14-16 02:49PM  ETFs with exposure to Zogenix, Inc. : November 14, 2016
Nov-09-16 11:33AM  Zogenix, Inc. :ZGNX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 9, 2016 +8.65%
Nov-08-16 08:00AM  Zogenix to Participate in Stifel 2016 Healthcare Conference GlobeNewswire +8.19%
06:07AM  ZOGENIX, INC. Files SEC form 10-Q, Quarterly Report
Nov-07-16 05:18PM  Zogenix reports 3Q loss
04:31PM  ZOGENIX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:01PM  Zogenix Provides Corporate Update and Reports Third Quarter 2016 Financial Results GlobeNewswire
07:07AM  Q3 2016 Zogenix Inc Earnings Release - After Market Close
Nov-03-16 04:02PM  ZOGENIX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
Nov-01-16 12:46PM  ETFs with exposure to Zogenix, Inc. : November 1, 2016
Oct-31-16 08:00AM  Zogenix to Release Third Quarter 2016 Financial Results and Host Conference Call and Webcast on November 7 GlobeNewswire
Oct-12-16 05:35PM  Humana, Pharma Stocks Sink as Healthcare is Worst Performing Sector Wednesday -7.06%
Oct-04-16 12:17PM  Leerink Rates Zogenix Outperform Ahead Of AES Meeting
Sep-27-16 08:32AM  ZOGENIX, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Sep-20-16 08:00AM  Zogenix to Participate in Two Upcoming Investor Conferences GlobeNewswire
Sep-15-16 10:55AM  ETFs with exposure to Zogenix, Inc. : September 15, 2016
Sep-08-16 04:05PM  Zogenix to have Significant Presence at 12th European Congress on Epileptology GlobeNewswire +6.44%
Aug-26-16 04:12PM  ZOGENIX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
Aug-15-16 11:00AM  ETFs with exposure to Zogenix, Inc. : August 15, 2016
Aug-12-16 12:54PM  Zogenix, Inc. :ZGNX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016
08:25AM  Why This Analyst Sees Huge Upside for Valeant and 2 More Specialty Pharmas at 24/7 Wall St.
Aug-09-16 07:26PM  Zogenix reports 2Q loss
04:18PM  ZOGENIX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:01PM  Zogenix Provides Corporate Update and Reports Second Quarter 2016 Financial Results GlobeNewswire
07:07AM  Q2 2016 Zogenix Inc Earnings Release - After Market Close
Aug-02-16 08:00AM  Zogenix to Release Second Quarter 2016 Financial Results and Host Conference Call and Webcast on August 9 GlobeNewswire
Jul-13-16 05:23PM  ZOGENIX, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Jul-11-16 08:01AM  ZOGENIX, INC. Files SEC form 8-K, Other Events
Jun-21-16 08:00AM  Zogenix Announces Agreement to Refinance Debt, Further Increasing Companys Expected 2017 Cash Balance GlobeNewswire
07:56AM  ZOGENIX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligati
Jun-07-16 08:06AM  ZOGENIX, INC. Files SEC form 8-K, Other Events +5.47%
08:00AM  Zogenix Announces Initiation of Multi-National Phase 3 Clinical Trial for ZX008 in Dravet Syndrome GlobeNewswire
May-31-16 08:00AM  Zogenix to Participate in Jefferies 2016 Healthcare Conference GlobeNewswire
May-24-16 03:51PM  ETFs with exposure to Zogenix, Inc. : May 24, 2016 +5.23%
May-23-16 12:13PM  Zogenix, Inc. :ZGNX-US: Earnings Analysis: Q1, 2016 By the Numbers : May 23, 2016
May-10-16 05:20PM  Zogenix reports 1Q loss
04:24PM  ZOGENIX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:01PM  Zogenix Provides Corporate Update and Reports First Quarter 2016 Financial Results GlobeNewswire
07:07AM  Q1 2016 Zogenix Inc Earnings Release - After Market Close
May-07-16 02:01PM  The Controversial Drug That Could Be Better at Controlling Seizures in Epilepsy Patients Than Marijuana at Motley Fool
May-05-16 06:13PM  ZOGENIX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
08:00AM  Zogenix Announces New Efficacy and Safety Data on ZX008 for Treatment of Seizures in Dravet Syndrome GlobeNewswire
May-03-16 08:00AM  Zogenix to Release First Quarter 2016 Financial Results and Host Conference Call and Webcast on May 10 GlobeNewswire
Apr-21-16 08:00AM  New Data on Zogenix's ZX008 for Dravet Syndrome to be Presented at 14th International Child Neurology Congress GlobeNewswire +6.23%
Apr-07-16 07:00AM  Cipher Pharmaceuticals Proposes Adding Rosemary A. Crane and Dr. Renee P. Tannenbaum To Board of Directors CNW Group
Mar-25-16 09:58AM  ETFs with exposure to Zogenix, Inc. : March 25, 2016
Mar-21-16 12:24PM  Zogenix, Inc. :ZGNX-US: Earnings Analysis: 2015 By the Numbers
Mar-15-16 04:16PM  Zogenix, Inc.: Strong price momentum but will it sustain? -5.51%
06:10AM  ZOGENIX, INC. Files SEC form 10-K, Annual Report
Mar-10-16 05:35PM  Zogenix reports 4Q loss -7.44%
04:10PM  ZOGENIX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:00PM  Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2015 Financial Results GlobeNewswire
03:41PM  Zogenix, Inc. Shares Galloped 15% Higher in February -- Here's Why at Motley Fool
07:07AM  Q4 2015 Zogenix Inc Earnings Release - After Market Close
Mar-04-16 08:00AM  Zogenix to Release Fourth Quarter and Full-Year 2015 Financial Results and Host Conference Call and Webcast on March 10 GlobeNewswire
Feb-03-16 08:00AM  Zogenix to Participate in LEERINK Partners 5th Annual Global Healthcare Conference GlobeNewswire
Jan-19-16 08:06AM  ZOGENIX, INC. Files SEC form 8-K, Other Events -6.18%
Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. The company's lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome. It also develops Relday, an injectable formulation of risperidone to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers with 13 years of age and older. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in Emeryville, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TANNENBAUM RENEE PDirectorMar 16Buy11.005,00055,00010,000Mar 20 06:25 PM